

Expert perspectives and practical guidance on targeting *MET* in advanced NSCLC

Chair

Sanjay Popat, FRCP, PhD, The Royal Marsden NHS, Foundation Trust and Institute of Cancer Research, London, UK

Faculty

David Ross Camidge, MD, PhD, University of Colorado, Aurora, CO, USA

Frank Griesinger, MD, PhD, Pius Hospital Oldenburg and University of Medicine Oldenburg, Oldenburg, Germany

Release date: July 30, 2021

Expiration date: July 30, 2022

Estimated time to completion: 1.0 hour

Available CME credits: UEMS-EACCME® accreditation pending

Activity description

This educational activity consists of one Expert Discussion and two Interactive Patient Cases.

During the Expert Discussion, leading experts will provide you with: insights on how to recognize and characterize *MET* dysregulations; clinical updates on the evolving treatment paradigm for *MET*-dysregulated advanced non-small-cell lung cancer (NSCLC); and practical tips on how to implement individualized evidence-based treatment plans in daily practice for the optimal clinical management of your patients.

The two interactive patient cases, will cover"

- The use of advanced diagnostic tools in guiding therapeutic decisions in *MET*ex14-positive NSCLC
- Overcoming *MET*-amplification-driven acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in *EGFR*-mutant NSCLC

Target audience

This activity is intended for oncologists, pulmonologists, pathologists, respiratory physicians, and other healthcare providers involved in the diagnosis, treatment and management of NSCLC patients.

Educational objectives

After completing this activity, the participant should be better able to:

- **Recognize** the unmet needs in the evolving treatment paradigm for *MET*-dysregulated advanced NSCLC
- **Describe** *MET* dysregulation mechanisms and the importance of accurate diagnostic *MET* assessment (e.g. liquid biopsy, NGS)

- **Evaluate** recent efficacy and safety data for *MET* inhibitor therapy in advanced NSCLC
- **Integrate** individualized evidence-based treatment plans in daily practice for the optimal clinical management of patients with *MET* dysregulated advanced NSCLC

Physician continuing medical education

An application for accreditation (1.0 ECMEC®) has been submitted to UEMS-EACCME® for this educational activity. More information is expected at the end of July 2021.

Method of participation and request for credit

There are no fees for participating in, and receiving CME/CE credit for, this activity.

In order to claim credit, participants must complete the following procedures during the period July 30, 2021, through July 30, 2022:

1. Read the educational objectives, accreditation information, and faculty disclosures
2. Complete the webcast and two interactive patient case activities
3. Take the post-activity test and complete the evaluation
4. Download the certificate of CME credit (If you have completed the evaluation form, you will be notified by email once the UEMS-EACCME® accreditation has been approved.)

Disclosure of conflicts of interest

Faculty	Relationship identified with:
Sanjay Popat, FRCP, PhD	Consultant for: Amgen, AstraZeneca, Bayer, BeiGene, Blueprint Medicines, BMS, Boehringer Ingelheim, Daiichi Sankyo, Guardant Health, Janssen, Lilly, Merck KGaA, Novartis, Roche, Takeda.
David Ross Camidge, MD, PhD	Grant/research funding recipient for: Inivata. Consultant for: AbbVie, Apollomics, AstraZeneca, Daiichi-Sankyo (ILD adjudication committee), Elevation Pharmaceuticals, Kestrel Pharmaceuticals, Nuvalent, Seattle Genetics, Takeda, Turning Point Therapeutics. Company-sponsored trials at institution (Principal Investigator role). for: AbbVie, AstraZeneca, Dizal Pharma, Inhibrx, Karyopharm, Pfizer, Phosplatin, PsiOxus Therapeutics, Rain Therapeutics, Roche/Genentech, Seattle Genetics, Takeda, Turning Point Therapeutics.

Frank Griesinger, MD, PhD	Consultant for: AbbVie, AstraZeneca, Aventis, Boehringer Ingelheim, Merck, MSD, Pfizer, Roche, Sanofi, Takeda.
---------------------------	--

Planners and managers

The Ology Medical Education planners and managers have nothing to disclose.

Provider information

Provided by Ology Medical Education.



Financial support

This activity is supported by an independent educational grant from Merck KGaA, Darmstadt, Germany.

Disclosure of unlabeled use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. The course materials are for educational purposes only and should not be reproduced or distributed in any way. If you wish to reproduce, store in a retrieval system, transmit in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, any part of the material presented, you will need to obtain all the necessary permissions by writing to the publisher, the original author, or any other current copyright owner.

Contact information for questions about the activity

info@ologyeducation.org, www.ologyeducation.org

System requirements

Ology Education requires a modern web browser (Google Chrome, Mozilla Firefox, Apple Safari, Microsoft Edge). Certain educational activities may require a PDF reader such as Adobe Acrobat Reader to view.

Policy on Privacy and Confidentiality

Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

Media

Internet